medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number 2

<< Back Next >>

Ann Hepatol 2006; 5 (2)

An experience with covered transjugular intrahepatic portosystemic shunt for refractory ascites from western India

Amarapurkar DN, Punamiya S, Patel ND

Language: English
References: 22
Page: 103-108
PDF size: 83.70 Kb.


Text Extraction

Background: In refractory ascites/hydrothorax (RA), uncovered transjugular intrahepatic portosystemic shunt (TIPS) is shown to be superior to large-volume therapeutic paracentesis (LVP) for long-term control of ascites, but at a cost of increased risk of hepatic encephalopathy (HE). Use of covered TIPS has shown to improve shunt patency rate over uncovered TIPS. This retrospective analysis was performed on patients with RA to assess efficacy of TIPS, both covered and uncovered. Methods: Over 10-year period, patients with RA, patients either required LVP at least 2 times in a month, or were intolerant to LVP, or were unwilling to undergo further LVP, were treated with TIPS (Group-A = 12 patients with uncovered TIPS {Wallstent = 10, Memotherm = 1, SMART = 1}, age = 56.1 ± 4.5 years, male: female = 5:1; Group-B = 11 patients with e-PTFE-covered TIPS {Viatorr = 11}, age = 55.8 ± 5.2 years, male: female = 8:3). They were followed-up with clinical and ultrasonography/ Doppler examination every monthly for 3 months and every 3 monthly thereafter (mean = 9.6 ± 4.2 months). Clinical success (disappearance of ascites at 1-month), technical success (post-TIPS reduction of portosystemic pressure gradient {PPG} ‹ 12 mmHg), appearance of encephalopathy, TIPS-dysfunction (› 50% reduction in flow-velocity, › 50% shunt stenosis or increase in PPG › 12 mmHg in presence of symptoms) and mortality were noted. Data were analyzed using chi-square test and t test. Results: Baseline clinical and biochemical characteristics were similar in both groups. TIPS placement was possible in 11/12 group-A and 11/ 11 group-B patients. Fall in PPG after TIPS was similar in both groups. One patient in group-A was lost followup after the procedure. On comparison of group-A and group-B, clinical success (63.3% and 81.8%), technical success (90.9% and 100%), occurrence of HE (60% and 54.4%) and mortality at 1-year (70% and 63.3%) were not significantly different. TIPS-dysfunction requiring re-intervention was significantly more common in group-A (50%) than group-B (0%). Conclusions: Covered TIPS was superior to uncovered TIPS, because of less TIPS-dysfunction without increasing chances of HE; but failed to offer any survival advantage.


REFERENCES

  1. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39: 841-856.

  2. Dudley F. Management of refractory ascites. J Gastroenterol Hepatol 2004; 19: S194-S199.

  3. Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis 1997; 17: 227-232.

  4. Boyer TD, Haskal ZJ. AASLD practice guideline: The role of Transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400.

  5. Deltenre P. Mathurin P, Dharancy S, Moreau R, Bulois P, Henrion J, Pruvot F, Ernst O, Paris J, Lebrec D. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liv International 2005; 25: 349-356.

  6. D’Amico G, Luca A, Morabito A, Miraglia R, D’Amico M. Uncovered Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129: 1282-1293.

  7. Albillos A, Banares R, Gonzalez M, Catalina M, Molinero L. A metaanalysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005; 43: 990-996.

  8. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996; 25: 135-144.

  9. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-1707.

  10. Gines P, Uriz J, Calaborra B, Garcia-Tsao G, Kamath PS, DelArbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-1847.

  11. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629-635.

  12. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al and the NASTRA group. The North American study for the treatment of refractory ascites. Gastroenterology 2003; 124: 634-641.

  13. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003; 124: 1700-1710.

  14. Saab S, Nieto JM, Ly D, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2004; 3: CD004889.

  15. Rosch J, Keller FS. Transjugular intrahepatic portosystemic shunt: present status, comparison with endoscopic therapy and shunt surgery, and future perspectives. World J Surg 2001; 25: 337-345.

  16. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-295.

  17. Bureau C, Gracia-Pagan J, Otal P, Pomier-Layargues G, Chabbert V, Cortez C, Perreault P, Peron J, Abraldes J, Bouchard L, Bilbao J, Bosch J, Rousseau H, Vinel J. Improved clinical outcome using polytetraflouroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469-475.

  18. Ockenga J, Kroencke T, Schuetz T, Plauth M, Kasim E, Petersein J, Schmidt H, Lochs H. Polytetraflouroethylene-covered Nitinol stentgraft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Scand J Gastroenterol 2004; 39: 994-999.

  19. Cejna M, Peck-Radosavljevic M, Thurnher SA, Hittmair K, Schoder M, Lammer J. Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetraflouroethylene-covered nitinol endoprosthesis. Radiology 2001; 221: 437-446.

  20. Otal P, Smayra T, Bureau C, Peron JM, Chabbert V, Chemla P, Joffre F, Vinel JP, Rousseau H. Preliminary results of a new expandedpolytetraflouroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures. Am J Roentgenol 2002; 178: 141-147.

  21. Sanyal AJ. Pros and cons of TIPS for refractory ascites. J Hepatol 2005; 43: 924-925.

  22. Jalan R, Lui HF, Redhead DN, Hayes PC. TIPSS 10 years on. Gut 2000; 46: 578-581.




2020     |     www.medigraphic.com